| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2014.08.048 |
| P698 | PubMed publication ID | 25171843 |
| P50 | author | Karen Canfell | Q70389126 |
| P2093 | author name string | Leonardo Simonella | |
| P2860 | cites work | Benefit of cervical screening at different ages: evidence from the UK audit of screening histories | Q24651273 |
| Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study | Q33444450 | ||
| Epidemiological and economic impact of human papillomavirus vaccines | Q33464848 | ||
| A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females | Q33514126 | ||
| Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop in Malmö, Sweden, May 9-10, 2009. | Q33893024 | ||
| Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. | Q33923869 | ||
| Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis | Q33975138 | ||
| Modelling in health economic evaluation. What is its place? What is its value? | Q34025535 | ||
| Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application | Q34025539 | ||
| Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review | Q34605012 | ||
| Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement | Q34636815 | ||
| A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer | Q34733919 | ||
| Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment | Q36444854 | ||
| Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease | Q36494809 | ||
| Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands | Q81355575 | ||
| Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial | Q81404025 | ||
| The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary | Q82564188 | ||
| HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness | Q82735078 | ||
| Health and economic impact associated with a quadrivalent HPV vaccine in Italy | Q82761914 | ||
| The Health Technology Assessment of bivalent HPV vaccine Cervarix in Italy | Q83104172 | ||
| Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands | Q84089766 | ||
| Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer | Q84305037 | ||
| Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model | Q84363995 | ||
| Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia | Q84563003 | ||
| A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme | Q84800235 | ||
| Cost-effectiveness of human papilloma virus vaccination in Iceland | Q84869945 | ||
| Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis | Q36534239 | ||
| Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK | Q36610489 | ||
| Cost-effectiveness analyses of human papillomavirus vaccination | Q36765963 | ||
| Economic evaluation of human papillomavirus vaccination in the United Kingdom | Q36818045 | ||
| Modeling preventative strategies against human papillomavirus-related disease in developed countries | Q37198208 | ||
| Structural differences among cost-effectiveness models of human papillomavirus vaccines | Q37259581 | ||
| Modeling cervical cancer prevention in developed countries | Q37291448 | ||
| Model for assessing human papillomavirus vaccination strategies | Q37302509 | ||
| Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination | Q37320896 | ||
| Evolution of the health economics of cervical cancer vaccination | Q37320899 | ||
| Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained. | Q37397788 | ||
| EUROGIN 2008 roadmap on cervical cancer prevention | Q37517461 | ||
| Economic evaluation of human papillomavirus vaccination in developed countries | Q37580639 | ||
| Empirically evaluating decision-analytic models | Q37709525 | ||
| Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia | Q37876979 | ||
| A brief history of economic evaluation for human papillomavirus vaccination policy | Q39846449 | ||
| Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark | Q39882847 | ||
| Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis | Q40026216 | ||
| Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty | Q40245291 | ||
| Meta-analysis of Pap test accuracy | Q40989993 | ||
| Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature | Q41714875 | ||
| Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom | Q43961793 | ||
| A multi-type HPV transmission model | Q44022221 | ||
| The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey | Q44033070 | ||
| Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands | Q44046271 | ||
| Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. | Q44765234 | ||
| Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. | Q50770674 | ||
| Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. | Q51134081 | ||
| Cost effectiveness of prophylactic HPV 16/18 vaccination in Finland: results from a modelling exercise. | Q51145676 | ||
| The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. | Q51701011 | ||
| Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. | Q51862683 | ||
| Human papillomavirus testing in primary cervical screening. | Q52338437 | ||
| A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. | Q53173185 | ||
| Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain | Q57076616 | ||
| Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine | Q57089428 | ||
| Colposcopy for the diagnosis of squamous intraepithelial lesions: A meta-analysis | Q60407217 | ||
| Recurrence after treatment by loop electrosurgical excision procedure (LEEP) of high-grade cervical intraepithelial neoplasia | Q73027235 | ||
| Decision analytic modelling in the economic evaluation of health technologies. A consensus statement. Consensus Conference on Guidelines on Economic Modelling in Health Technology Assessment | Q74287472 | ||
| The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada | Q80462054 | ||
| Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France | Q80545520 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 34-51 | |
| P577 | publication date | 2014-08-27 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries | |
| P478 | volume | 33 |
| Q90035185 | HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control |
| Q55385410 | Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related Human Papillomavirus and Cost-Effectiveness of Prevention. |
| Q55397815 | Simple but not simpler: a systematic review of Markov models for economic evaluation of cervical cancer screening. |
| Q36325832 | Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend. |
Search more.